This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Stocks in S&P 500 ETF That Braved the Worst Start Since 2016
by Sweta Killa
The S&P 500 had the worst start to a year since 2016, reflecting a sharp reversal of the roaring rally in the final two months of 2023. Despite the losses, some stocks in the ETF stood tall.
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024
by Ekta Bagri
REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.
Select Medical (SEM) Unveils Separation Plan for Concentra
by Zacks Equity Research
Select Medical (SEM) intends to separate its Concentra business in a bid to enhance shareholder value and boost growth prospects of strategically prioritized areas.
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
by Zacks Equity Research
Here is how Aclaris Therapeutics (ACRS) and Regeneron (REGN) have performed compared to their sector so far this year.
Earnings Estimates Moving Higher for Regeneron (REGN): Time to Buy?
by Zacks Equity Research
Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Regeneron (REGN) Surges 3.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Regeneron (REGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Best Momentum Stocks to Buy for January 3rd
by Zacks Equity Research
SRPT, WING and REGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024.
Top 5 Momentum Picks for January After a Fabulous 2023
by Nalak Das
We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.
Buy These 4 Low-Beta Stocks to Counter Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Otter Tail (OTTR), Regeneron (REGN), Kanzhun Limited (BZ) and Stride (LRN) are well-poised to gain.
Bayer (BAYRY) Loses 28% in 2023: What to Expect in 2024?
by Zacks Equity Research
Bayer (BAYRY) faced challenges in 2023 as sales declined in the Crop Science division. Pipeline setbacks also weighed on the stock.
The Zacks Analyst Blog Highlights Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK
by Zacks Equity Research
Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK are included in this Analyst Blog.
5 Big Drug Stocks That May Continue to Outperform in 2024
by Kinjel Shah
Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
Top Analyst Reports for Chevron, SAP & United Parcel Service
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), SAP SE (SAP) and United Parcel Service, Inc. (UPS).
Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate
by Zacks Equity Research
Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.
Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus
by Zacks Equity Research
Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.
EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data
by Zacks Equity Research
EyePoint (EYPT) announces positive top-line data from the phase II study of its investigational candidate, EYP-1901, in the treatment of wet age-related macular degeneration. The stock rallies 178%.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi (SNY) post positive data from the second COPD study and plan to submit a sBLA to the FDA by the end of 2023.
Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How
by Zacks Equity Research
Kiniksa Pharmaceuticals (KNSA) enjoys a good run in the year on the back of solid revenue growth and pipeline updates.
Regeneron (REGN) Stock Rallies 10% YTD: What Lies Ahead?
by Zacks Equity Research
Regeneron (REGN) shares gain 10% year to date on Eylea HD's approval and Dupixent's momentum. Pipeline progress is impressive as well.
HRMY vs. REGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRMY vs. REGN: Which Stock Is the Better Value Option?
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Intellia (NTLA) Rises on EC's Orphan Drug Tag for HAE Candidate
by Zacks Equity Research
The European Commission bestows orphan drug designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema. Stock rises.
Intellia (NTLA) Beats on Q3 Earnings, Provides Pipeline Update
by Zacks Equity Research
Intellia (NTLA) reports mixed third-quarter 2023 results. Management provides developmental and regulatory updates on its key pipeline candidates.
Bayer's (BAYRY) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Bayer (BAYRY) reports weaker-than-expected third-quarter 2023 results. Management maintains its 2023 outlook.